Publications

Found 4 results
Filters: Author is F. Richeti  [Clear All Filters]
2012
R. B. Castro, Longui, C. A., Faria, C. D. C., Silva, T. S., Richeti, F., Rocha, M. N., Melo, M. R., Pereira, W. L., Chamlian, E. G., and Rivetti, L. A., Tissue-specific adaptive levels of glucocorticoid receptor alpha mRNA and their relationship with insulin resistance, vol. 11, pp. 3975-3987, 2012.
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, et al. (2009). Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 94: 2692-2701. http://dx.doi.org/10.1210/jc.2009-0370 PMid:19470627   Balachandran A, Guan H, Sellan M, van US, et al. (2008). Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 149: 4069-4079. http://dx.doi.org/10.1210/en.2008-0088 PMid:18467433 PMCid:2488250   Bansilal S, Farkouh ME and Fuster V (2007). Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am. J. Cardiol. 99: 6B-14B. http://dx.doi.org/10.1016/j.amjcard.2006.11.002 PMid:17307054   Benetos A, Thomas F, Pannier B, Bean K, et al. (2008). All-cause and cardiovascular mortality using the different definitions of metabolic syndrome. Am. J. Cardiol. 102: 188-191. http://dx.doi.org/10.1016/j.amjcard.2008.03.037 PMid:18602519   Deveci E, Yesil M, Akinci B, Yesil S, et al. (2009). Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin. Cardiol. 32: 32-36. http://dx.doi.org/10.1002/clc.20379 PMid:19143010   Di Blasio AM, van Rossum EF, Maestrini S, Berselli ME, et al. (2003). The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. 59: 68-74. http://dx.doi.org/10.1046/j.1365-2265.2003.01798.x   Duma D, Jewell CM and Cidlowski JA (2006). Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102: 11-21. http://dx.doi.org/10.1016/j.jsbmb.2006.09.009 PMid:17070034   Escher G, Galli I, Vishwanath BS, Frey BM, et al. (1997). Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J. Exp. Med. 186: 189-198. http://dx.doi.org/10.1084/jem.186.2.189 PMid:9221748 PMCid:2198986   Faria CD, Castro RB, Longui CA, Kochi C, et al. (2010). Impact of prolonged low-grade physical training on the in vivo glucocorticoid sensitivity and on glucocorticoid receptor-alpha mRNA levels of obese adolescents. Horm. Res. Paediatr. 73: 458-464. http://dx.doi.org/10.1159/000313591 PMid:20407233   Fernandes-Rosa FL, Bueno AC, de Souza RM, de CM, et al. (2010). Mineralocorticoid receptor p.I180V polymorphism: association with body mass index and LDL-cholesterol levels. J. Endocrinol. Invest. 33: 472-477. PMid:19955850   Gathercole LL, Bujalska IJ, Stewart PM and Tomlinson JW (2007). Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J. Clin. Endocrinol. Metab. 92: 4332-4339. http://dx.doi.org/10.1210/jc.2007-1399 PMid:17711920   Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, et al. (2006). The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res. Clin. Pract. 72: 219-220. http://dx.doi.org/10.1016/j.diabres.2005.10.017 PMid:16310881   Georgakopoulos A and Tsawdaroglou N (1996). Insulin potentiates the transactivation potency of the glucocorticoid receptor. FEBS Lett. 381: 177-182. http://dx.doi.org/10.1016/0014-5793(96)00115-9   Gesina E, Blondeau B, Milet A, Le N, I, et al. (2006). Glucocorticoid signalling affects pancreatic development through both direct and indirect effects. Diabetologia 49: 2939-2947. http://dx.doi.org/10.1007/s00125-006-0449-3 PMid:17001468 PMCid:1885455   Goedecke JH, Wake DJ, Levitt NS, Lambert EV, et al. (2006). Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin. Endocrinol. 65: 81-87. http://dx.doi.org/10.1111/j.1365-2265.2006.02552.x PMid:16817824   Gross KL, Lu NZ and Cidlowski JA (2009). Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell Endocrinol. 300: 7-16. http://dx.doi.org/10.1016/j.mce.2008.10.001 PMid:19000736 PMCid:2674248   Hoppmann J, Perwitz N, Meier B, Fasshauer M, et al. (2010). The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J. Endocrinol. 204: 153-164. http://dx.doi.org/10.1677/JOE-09-0292 PMid:19939912   Longui CA and Faria CD (2009). Evaluation of glucocorticoid sensitivity and its potential clinical applicability. Horm. Res. 71: 305-309. http://dx.doi.org/10.1159/000223413 PMid:19506386   Löwenberg M, Tuynman J, Scheffer M, Verhaar A, et al. (2006). Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. Endocrinology 147: 3555-3562. http://dx.doi.org/10.1210/en.2005-1602 PMid:16574792   Lu NZ and Cidlowski JA (2005). Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol. Cell 18: 331-342. http://dx.doi.org/10.1016/j.molcel.2005.03.025 PMid:15866175   Lundgren M, Buren J, Ruge T, Myrnas T, et al. (2004). Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 89: 2989-2997. http://dx.doi.org/10.1210/jc.2003-031157 PMid:15181089   Masuzaki H, Paterson J, Shinyama H, Morton NM, et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170. http://dx.doi.org/10.1126/science.1066285 PMid:11739957   Melo MR, Faria CD, Melo KC, Reboucas NA, et al. (2004). Real-time PCR quantitation of glucocorticoid receptor alpha isoform. BMC Mol. Biol. 5: 19. http://dx.doi.org/10.1186/1471-2199-5-19 PMid:15507144 PMCid:529441   Mericq V, Medina P, Bouwman C, Johnson MC, et al. (2009). Expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 enzyme in subcutaneous and visceral adipose tissue of prepubertal children. Horm. Res. 71: 89-93. http://dx.doi.org/10.1159/000183897 PMid:19129713   Reaven GM (2008). Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol. Metab. Clin. North Am. 37: 581-viii. http://dx.doi.org/10.1016/j.ecl.2008.06.005 PMid:18775353   Rebuffé-Scrive M, Bronnegard M, Nilsson A, Eldh J, et al. (1990). Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71: 1215-1219. http://dx.doi.org/10.1210/jcem-71-5-1215 PMid:2229280   Reynolds RM, Chapman KE, Seckl JR, Walker BR, et al. (2002). Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA 287: 2505-2506. http://dx.doi.org/10.1001/jama.287.19.2505 PMid:12020330   Rosenbaum P and Ferreira SRG (2003). An update on cardiovascular risk of metabolic syndrome. Arq. Bras. Endocrinol. Metab. 47: 220-227. http://dx.doi.org/10.1590/S0004-27302003000300004   Sousa Silva T, Longui CA, Rocha MN, Faria CD, et al. (2010). Prolonged physical training decreases mRNA levels of glucocorticoid receptor and inflammatory genes. Horm. Res. Paediatr. 74: 6-14. http://dx.doi.org/10.1159/000313586 PMid:20407229   Stewart PM (2005). Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome - 11beta-hydroxysteroid dehydrogenase type 1. Clin. Med. 5: 142-146. PMid:15847006   Vegiopoulos A and Herzig S (2007). Glucocorticoids, metabolism and metabolic diseases. Mol. Cell Endocrinol. 275: 43-61. http://dx.doi.org/10.1016/j.mce.2007.05.015 PMid:17624658   Wake DJ, Rask E, Livingstone DE, Soderberg S, et al. (2003). Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88: 3983-3988. http://dx.doi.org/10.1210/jc.2003-030286 PMid:12915696   Wallace AD and Cidlowski JA (2001). Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276: 42714-42721. http://dx.doi.org/10.1074/jbc.M106033200 PMid:11555652   Wallace TM, Levy JC and Matthews DR (2004). Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495. http://dx.doi.org/10.2337/diacare.27.6.1487 PMid:15161807   Wang M (2005). The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr. Metab. 2: 3. http://dx.doi.org/10.1186/1743-7075-2-3 PMid:15689240 PMCid:548667   Wassink AM, Van Der Graaf Y, Olijhoek JK and Visseren FL (2008). Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur. Heart J. 29: 213-223. http://dx.doi.org/10.1093/eurheartj/ehm582 PMid:18199567   Webster JC, Jewell CM, Bodwell JE, Munck A, et al. (1997). Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272: 9287-9293. http://dx.doi.org/10.1074/jbc.272.14.9287 PMid:9083064   Whorwood CB, Donovan SJ, Wood PJ and Phillips DI (2001). Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J. Clin. Endocrinol. Metab. 86: 2296-2308. http://dx.doi.org/10.1210/jc.86.5.2296 PMid:11344242   Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, et al. (2002). Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51: 1066-1075. http://dx.doi.org/10.2337/diabetes.51.4.1066 PMid:11916927   Zennaro MC, Caprio M and Feve B (2009). Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol. Metab. 20: 444-451. http://dx.doi.org/10.1016/j.tem.2009.05.006 PMid:19800255